Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVEMIR PENFILL vs LEVEMIR INNOLET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Insulin detemir is a long-acting insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake in peripheral tissues (muscle, adipose) and inhibit hepatic glucose production. The addition of a fatty acid chain (myristic acid) to the lysine at position B29 allows reversible binding to albumin, prolonging its duration of action.
Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.
Glycemic control in patients with diabetes mellitus (FDA approved for type 1 and type 2 diabetes),Off-label: Use in gestational diabetes with insulin
FDA: Treatment of diabetes mellitus (type 1 and type 2) to improve glycemic control,Off-label: Gestational diabetes, hyperglycemia in hospitalized patients
Subcutaneous injection, starting dose 0.2–0.3 units/kg once daily, titrated to target glucose. Type 1 diabetes: typically 0.3–0.5 units/kg/day. Type 2 diabetes: 10 units once daily, adjusted based on blood glucose.
0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.
Terminal half-life: approximately 13-14 hours (range 12-18 hours) after subcutaneous administration in patients with type 1 diabetes, reflecting prolonged absorption from the injection site. The long half-life supports once-daily dosing.
Terminal elimination half-life is 13–14 hours after subcutaneous administration, providing a flat, protracted pharmacokinetic profile suitable for once-daily dosing.
Degraded by general protein catabolism. No specific CYP450 metabolism; cleared via receptor-mediated endocytosis and subsequent intracellular degradation into inactive metabolites.
Insulin detemir is metabolized via non-CYP450 pathways, primarily proteolytic degradation. The main metabolite is inactive.
Renal: negligible; metabolized by proteolytic degradation, primarily in the liver and kidneys; <1% excreted unchanged in urine. Fecal: minor.
Hepatic metabolism (deamidation at B30 and deacetylation at B29) and subsequent renal excretion; ~30% of dose excreted unchanged in urine.
>98% bound to albumin; binding is reversible and concentration-dependent.
>98% bound to albumin; binding is reversible and saturated at therapeutic concentrations.
Approximately 0.1 L/kg (range 0.05-0.2 L/kg), indicating distribution primarily into extracellular fluid; Vd is relatively small due to albumin binding.
Volume of distribution is approximately 0.26–0.38 L/kg, reflecting distribution primarily into interstitial fluid.
Subcutaneous: approximately 60-80% after injection; bioavailability is nearly complete compared to other insulin analogs, but may be slightly lower due to local degradation.
Subcutaneous: approximately 60–80% absolute bioavailability; not administered by other routes.
GFR <30 m L/min: reduce dose by 25–50% due to reduced insulin clearance; monitor glucose closely. GFR 30-60 m L/min: no formal adjustment but cautious titration. Not studied in dialysis.
For GFR <30 m L/min: consider dose reduction and more frequent monitoring due to decreased insulin clearance; start with lower doses and titrate cautiously. No specific dose adjustment guidelines for GFR 30-89 m L/min, but monitor closely.
Child-Pugh Class B or C: reduce dose by 25–50% due to decreased gluconeogenesis; monitor for hypoglycemia. No specific data for Class A.
Child-Pugh Class A (mild): no dose adjustment required. Child-Pugh Class B (moderate): start with lower doses and titrate slowly due to impaired gluconeogenesis and reduced insulin clearance. Child-Pugh Class C (severe): use with caution; consider starting at 50% of standard dose and titrate based on response.
Weight-based: 0.2–0.5 units/kg/day subcutaneously, typically once daily. Titrate by 2–4 units based on fasting glucose. Not approved for children <6 years.
For children aged 2 years and older with type 1 diabetes: start at 0.2-0.5 units/kg subcutaneously once daily in the evening. For type 2 diabetes: limited data; based on adult dosing. Adjust dose based on blood glucose targets. Do not mix with other insulins.
Initiate at lower doses (e.g., 5–10 units once daily) due to renal impairment, polypharmacy, and increased hypoglycemia risk. Titrate slowly, monitor glucose frequently.
In elderly patients (age ≥65 years), start at lower doses (e.g., 0.1 units/kg subcutaneously once daily) due to increased risk of hypoglycemia. Titrate slowly and monitor renal function. Avoid aggressive dose escalation.
Not indicated for treatment of diabetic ketoacidosis; do not use during episodes of hypoglycemia. Accidental mix-ups with other insulins (e.g., insulin degludec, insulin glargine) have caused severe hypoglycemia.
None
Hypoglycemia (most common adverse reaction; may be severe and life-threatening),Do not dilute or mix with other insulins in the same syringe,Thiazolidinediones (TZDs) coadministration may increase risk of fluid retention and heart failure,Renal or hepatic impairment may increase hypoglycemic risk; dose adjustment may be needed,Not recommended for insulin pump use
Hypoglycemia: May be life-threatening; dose adjustment needed with renal/hepatic impairment,Medication errors: Do not confuse with other insulins; not for IV or IM use,Hypokalemia: Can cause low potassium, leading to cardiac arrhythmias,Fluid retention and heart failure: When used with thiazolidinediones (TZDs)
Hypersensitivity to insulin detemir or any excipients,During episodes of hypoglycemia
Hypoglycemia episodes,Hypersensitivity to insulin detemir or excipients,Not recommended for diabetic ketoacidosis (use short-acting insulin)
No specific food interactions. However, timing of meals should be consistent with insulin action. Carbohydrate intake must be balanced with insulin dose to prevent hyperglycemia or hypoglycemia. Alcohol may potentiate hypoglycemic effect; limit intake and monitor glucose.
No specific food interactions. Advise consistent carbohydrate intake to match insulin dose. Alcohol may increase hypoglycemia risk; avoid or limit alcohol consumption.
Insulin detemir (Levemir Penfill) does not cross the placenta in significant amounts. No increased risk of major congenital anomalies has been observed in humans. Poorly controlled diabetes increases risk for fetal malformations and neonatal complications. Strict glycemic control is recommended before conception and throughout pregnancy.
Insulin detemir does not cross the placenta in significant amounts. Animal studies show no evidence of teratogenicity. In humans, no increased risk of major malformations in first trimester; risks in second and third trimesters relate to maternal hyperglycemia, not drug. Poor glycemic control increases risk of fetal anomalies, macrosomia, neonatal hypoglycemia.
Insulin detemir is a large protein molecule and is not expected to transfer into breast milk in clinically relevant amounts. M/P ratio not established; endogenous insulin is present in breast milk. Considered compatible with breastfeeding; monitor infant for hypoglycemia if large doses are used.
Insulin detemir is excreted in human milk in low amounts, unlikely to affect the infant. M/P ratio not reported. It is a peptide that is degraded in infant GI tract. Use during breastfeeding is considered compatible with caution to monitor infant blood glucose if maternal dose is high.
Pregnancy induces insulin resistance, especially in second and third trimesters; dose requirements typically increase (may double or more). Postpartum dose reduction is often needed due to sudden drop in insulin resistance. Individualized titration based on frequent blood glucose monitoring.
Pregnancy increases insulin requirements, especially in second and third trimesters. Dose adjustments typical: first trimester may require 0-20% reduction due to increased hypoglycemia risk; second trimester increase by 50-70%; third trimester increase by 100-150% above pre-pregnancy doses. Frequent monitoring and titration are essential.
Insulin detemir (LEVEMIR PENFILL) is a long-acting basal insulin analogue with a duration of action up to 24 hours, but may require twice-daily dosing in some patients. It has a unique mechanism of albumin binding, resulting in less variable absorption and a flatter pharmacokinetic profile compared to NPH insulin. Do not mix with other insulins in the same syringe. Onset is gradual (3-4 hours), peakless, and duration dose-dependent. Use cautiously in renal or hepatic impairment; dose adjustments may be needed.
Levemir (insulin detemir) is a long-acting basal insulin analog with a duration of action up to 24 hours. It has a lower risk of hypoglycemia compared to NPH insulin due to its flat pharmacokinetic profile. Administer once or twice daily at the same time(s) each day. Do not mix with other insulins in the same syringe. Store unopened vials/penfills in refrigerator; opened pens can be kept at room temperature (<30°C) for up to 42 days. Monitor renal and hepatic function as dose adjustments may be needed.
Inject subcutaneously once or twice daily at the same time each day.,Rotate injection sites (abdomen, thigh, upper arm) to prevent lipodystrophy.,Do not mix with other insulins in the same syringe.,Monitor blood glucose regularly, especially when starting, changing dose, or during illness.,Store unopened pens in refrigerator (2-8°C); opened pens can be kept at room temperature (below 30°C) for up to 28 days.,Avoid alcohol consumption which can increase risk of hypoglycemia.,Recognize symptoms of hypoglycemia (sweating, dizziness, confusion) and hyperglycemia (thirst, frequent urination, blurred vision).,Do not share pens with others, even if needle changed.
Inject subcutaneously into abdomen, thigh, or upper arm; rotate injection sites to avoid lipodystrophy.,Do not mix with other insulins; use a separate injection site if combining therapies.,Check blood glucose regularly and record results; know symptoms of hypoglycemia and hyperglycemia.,Do not use if solution appears cloudy or has particles; it should be clear and colorless.,Store unopened pens in refrigerator; opened pens can be kept at room temperature for up to 42 days away from heat or light.,Missed dose: take as soon as remembered unless next dose is due within 6 hours; never double dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVEMIR PENFILL vs LEVEMIR INNOLET, answered by our medical review team.
LEVEMIR PENFILL is a Antidiabetic (Long-Acting Insulin) that works by Insulin detemir is a long-acting insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake in peripheral tissues (muscle, adipose) and inhibit hepatic glucose production. The addition of a fatty acid chain (myristic acid) to the lysine at position B29 allows reversible binding to albumin, prolonging its duration of action.. LEVEMIR INNOLET is a Antidiabetic (Long-Acting Insulin) that works by Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVEMIR PENFILL and LEVEMIR INNOLET depend on the specific clinical indication. These are both Antidiabetic (Long-Acting Insulin) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVEMIR PENFILL is: Subcutaneous injection, starting dose 0.2–0.3 units/kg once daily, titrated to target glucose. Type 1 diabetes: typically 0.3–0.5 units/kg/day. Type 2 diabetes: 10 units once daily, adjusted based on blood glucose.. The standard adult dose of LEVEMIR INNOLET is: 0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVEMIR PENFILL and LEVEMIR INNOLET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVEMIR PENFILL is classified as Category C. Insulin detemir (Levemir Penfill) does not cross the placenta in significant amounts. No increased risk of major congenital anomalies has been observed in humans. Poorly controlled. LEVEMIR INNOLET is classified as Category C. Insulin detemir does not cross the placenta in significant amounts. Animal studies show no evidence of teratogenicity. In humans, no increased risk of major malformations in first . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.